#Risk level small medium micro cap stocks trial#
We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101. At the time of the announcement, Aerovate CEO Tim Noyes said… The trial will evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in adult patients with Pulmonary Arterial Hypertension (PAH). In December, the company announced the initiation of its Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 trial. The company focuses on therapies for rare cardiopulmonary diseases. Aerovate TherapeuticsĪerovate Therapeutics is a clinical-stage biotech company. As a result, this progress makes this small cap biotech stock an intriguing prospect. It plans to file an IND for VRDN-001 in Q4 2021. The company filed an Investigational New Drug (IND) application for VRDN-001 in October 2021.
/GettyImages-1055247044-5247effcffdd4770bc3493959899a2dd.jpg "risk level small medium micro cap stocks")
The product is distinct from VRDN-001 due to its half-life extension technology and subcutaneous administration. It is suitable for all non-oncology indications that do not involve radiopharmaceuticals, including the treatment of TED.įurthermore, the company is developing a second-generation candidate, VDRN-002. In 2020, the company obtained exclusive rights from ImmunoGen to develop, manufacture and commercialize VRDN-001. Viridian’s development plans for VRDN-001 are informed by pharmacokinetic, pharmacodynamic, safety and tolerability data collected in that program. ImmunoGen previously developed the IGF-1R antibody. Viridian’s lead program, VRDN-001, is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for thyroid eye disease.
The company’s headquarters are in Boulder, Colorado, with research and development operations in Waltham, Massachusetts. Viridian Therapeutics is a biotechnology company advancing new treatments for serious diseases that are underserved. As a result, Dynavax is one of the top small cap biotech stocks to watch in 2022.
#Risk level small medium micro cap stocks driver#
This should be a huge growth driver for the company over 2022. While driving revenue, the company collaborates with other companies to advance the adjuvant as a premier vaccine adjuvant.Ĭurrent collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap and universal influenza. Moreover, the company is leveraging its CpG 1018 adjuvant to provide long-term value. and the European Union.ĭynavax’s HEPLISAV-B contains a proprietary toll-like receptor 9 agonist adjuvant called CpG 1018. HEPLISAV-B is approved and commercialized in the U.S. Specifically, the company has developed HEPLISAV-B, a vaccine to help prevent subtypes of the Hepatitis B virus in adults 18 years and older. These are a few small cap biotech stocks to watch closely in 2022…ĭynavax is a biopharmaceutical company that uses Toll-like receptor biology for the development of vaccines. To make things easier, we’ve put together a list of small cap biotech stocks worth watching. It’s important to judge biotech stocks as more companies enter the market. So, if you can stomach high-risk investments with the potential for high returns, small cap biotech stocks might be your cup of tea. However, you should know that the industry comes with some risks. There’s an opportunity for big gains in the biotechnology sector. Furthermore, new advances in science are opening doors for the treatment and prevention of diseases like never before. As a result, biotech companies are able to better target illnesses. Humanity is continuing to take leaps in understanding human biology and the biology of various diseases. These companies are the future of modern medicine. However, biotech, covers far more than vaccine developments. 2021 proved to be a record-setting year with the development of vaccines for the pandemic. Moreover, this presents a unique opportunity for investors.ĬOVID-19 brought a lot of attention to the biopharmaceutical industry. Many scientists believe that we’re in the golden age of innovation in the ways we treat diseases. Small cap biotech stocks are giving investors new ways to make big money.
0 kommentar(er)
